NDAINTRAVENOUSSOLUTION
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
DAPTOMYCIN IN 0.9% SODIUM CHLORIDE (daptomycin in sodium chloride) by Baxter is 12. Approved for pneumonia, left-sided infective endocarditis due to s, complicated skin and 16 more indications. First approved in 2022.
Drug data last refreshed 12h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Daptomycin in 0.9% Sodium Chloride is a ready-to-use IV lipopeptide antibiotic formulation approved in 2022 for treating serious Gram-positive bacterial infections including bloodstream infections, infective endocarditis, and complicated skin infections. It works by disrupting bacterial cell membranes, with efficacy correlating to AUC/MIC ratio. This pre-filled formulation eliminates the need for reconstitution, streamlining hospital pharmacy workflows.
Peak14.7 years to LOE
Peak lifecycle product with 14.7 years of patent protection remaining; commercial team expansion likely but market maturation and generic competition pose medium-term headwinds.
Mechanism of Action
12.1 Mechanism of Action Daptomycin is an antibacterial drug [see ] . 12.2 Pharmacodynamics Based on animal models of infection, the antimicrobial activity of daptomycin appears to correlate with the AUC/MIC (area under the concentration-time curve/minimum inhibitory concentration) ratio for…
Worked on DAPTOMYCIN IN 0.9% SODIUM CHLORIDE at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.